Alzheimer’s

Lilly Biotechnology Center
#Alzheimer's #Eli Lilly #National Institute for Health and Care Excellence (NICE) #NHS

Lilly wins appeal for donanemab, drug to be reconsidered for NHS 

Eli Lilly’s appeal against guidance which did not recommend donanemab has been upheld, forcing authorities to reconsider the drug for NHS use.  The National Institute for Health and Care Excellence (NICE) published the outcome for Lilly’s appeal, after final draft guidance had not recommended NHS reimbursement of donanemab for the treatment of mild cognitive… Read More

#News

#Alzheimer's #Brain #Breast cancer #Dementia #Genetics #Immunology #Institute of Cancer Research #King's College London #Neuroscience #Parkinson's #Respiratory syncytial virus #Women's health

DDW Highlights: 17 March 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, research on the brain proved a popular theme, unlocking insights into Alzheimer’s, dementia… Read More

#Podcasts

#Alzheimer's #Brain #Breast cancer #Dementia #Genetics #Immunology #Institute of Cancer Research #King's College London #Neuroscience #Parkinson's #Respiratory syncytial virus #Women's health

This week in Drug Discovery (9 – 13 March) 

News round-up for 9 – 13 March February by Bruno Quinney, Content Team at DDW.  This week, research on the brain has proved a popular theme, unlocking insights into Alzheimer’s, dementia and cancer. Elsewhere, a genetic target could provide new routes to breast cancer treatment.  The top stories: … Read More

#News

Neurons with Lewy bodies
#Alzheimer's #Mayo Clinic #Neuroscience #Women's health

Parkinson’s protein linked to faster Alzheimer’s progression in women

Alzheimer’s-related brain changes progressed up to 20 times faster in women who also had abnormal levels of a Parkinson’s-related protein, according to a Mayo Clinic study.  The findings suggest that when alpha-synuclein — a protein linked to Parkinson’s disease — accumulates alongside Alzheimer’s pathology, it may drive… Read More

#Editor's Choice #News

Microglia in the brain
#Alzheimer's #Dementia #Neuroscience #Texas A&M University Health Science Center

Could extracellular vesicle therapy prevent dementia?

A new research project will test whether extracellular vesicle (EV) therapy can prevent—or even reverse—inflammation in the brain linked to dementia.  Texas A&M Health and the Division of Research created the Dementia & Alzheimer’s Research Initiative (DARI) to prevent, more quickly detect and more effectively treat dementia. … Read More

#Editor's Choice #News

#Alzheimer's #Bacteria #Brain cancer #Cancer immunotherapy #Clinical trial #Drug resistance #Fast Track designation #FDA #Gene therapy #Life sciences #Melanoma #Siren Biotechnology #UK government #University of Sydney

DDW Highlights: 10 February 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, innovative therapies showed the way to more effective cancer treatments. Elsewhere, how can… Read More

#Podcasts

#Alzheimer's #Bacteria #Brain cancer #Cancer immunotherapy #Clinical trial #Drug resistance #Fast Track designation #FDA #Gene therapy #Life sciences #Melanoma #Siren Biotechnology #UK #UK government #University of Sydney

This week in Drug Discovery (2 – 6 February) 

News round-up for 2 – 6 February by Bruno Quinney, Content Team at DDW.  This week in DDW, innovative therapies could pave the way to more effective cancer treatments. Elsewhere, how can brain function be improved in Alzheimer’s patients?  The top stories:      Immunotherapy before surgery… Read More

#News

CT scans of the brain
#Alzheimer's #Biopharma #Clinical trial #Fast Track designation #FDA

Therapy could improve brain function in Alzheimer’s patients

An investigational therapy could improve cognition, function and brain atrophy measures in Alzheimer’s patients, data shows.  Valiltramiprosate, which received Fast Track designation from the US Food and Drug Administration (FDA) in 2017, is an investigational oral agent being evaluated as a potential first-in-class, disease-modifying treatment for Alzheimer’s disease… Read More

#News

Antibodies
#Alzheimer's #Neuroscience #Novartis #SciNeuro Pharmaceuticals #Therapeutic Antibodies

Novartis and SciNeuro collaborate on antibodies for Alzheimer’s

Novartis Pharma and SciNeuro Pharmaceuticals have agreed a worldwide licensing and collaboration agreement to advance SciNeuro’s novel amyloid beta targeted antibody programme for the treatment of Alzheimer’s disease.    The programme has identified de novo antibody candidates that incorporate SciNeuro’s proprietary blood brain barrier shuttle technology… Read More

#Business & Investment #News

Node structures in the central nervous system
#Alzheimer's #Biotech #CNS #Insilico Medicine #Parkinson's

Insilico and Hygtia Therapeutics partner on CNS disease drug 

Biotechnology companies Insilico Medicine and Hygtia Therapeutics have announced a co-development collaboration agreement for Insilico’s ISM8969.  The partnership will look to accelerate the global advancement of ISM8969, an orally available, brain penetrant NLRP3 inhibitor for Central Nervous System (CNS) disorders.   The NLRP3 inflammasome is a critical component of the innate immune system but… Read More

#Business & Investment #News

#AI / data analytics / healthtech / informatics #Alzheimer's #Drug discovery #Oncology #Regulatory #Spatial biology

DDW Winter issue out now

The DDW Winter 2025/2026 issue is out now and includes features covering the advances and challenges in blood cancer drug development, how the Baltics is implementing a new action plan for its life sciences sectors, and how spatial epigenetics is unlocking new frontiers for drug discovery.  It also… Read More

#News

#AI #Allergen immunotherapy #Allergy #Alzheimer's #Biotech #China #Clinical trial #DDW Highlights podcast #Eli Lilly #Obesity #Osteoarthritis #Spinogenix

DDW Highlights: 16 December 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, innovative treatments showed potential to treat neurodegenerative diseases, allergies and arthritis. Elsewhere,… Read More

#Podcasts

#AI #Allergen immunotherapy #Allergy #Alzheimer's #Biotech #China #Clinical trial #Eli Lilly #Obesity #Osteoarthritis #Spinogenix

This week in Drug Discovery (8 – 12 December) 

News round-up for 8 – 12 December by Bruno Quinney, Content Team at DDW.  This week in DDW, innovative treatments have been developed for neurodegenerative diseases, allergies and arthritis. Elsewhere, China is becoming the dominant force in the biotech sector.  The top stories:   … Read More

#News

MRI of dementia patient
#Alzheimer's #Biomarkers #Duke University #Neurodegenerative disorders #Neuroscience

Study supports hippocampal volume as marker in Alzheimer’s

A new study has revealed that hippocampal volume (HV) may be a reliable and measurable surrogate used to assess clinical benefits in early Alzheimer’s disease.  The study results, published in the scientific journal CNS Drugs, show that shrinkage of the hippocampus… Read More

#Editor's Choice #News

Pills
#Alzheimer's #Clinical trial #Spinogenix

Once-a-day pill could reverse cognitive decline, trial shows 

A new once-a-day pill could reverse cognitive decline in Alzheimer’s patients, a clinical trial has shown.  Tazbentetol, developed by biopharmaceutical company Spinogenix, demonstrated rapid, sustained cognitive improvement in a Phase IIa trial. The randomised, double-blind, placebo-controlled trial enrolled 24 patients in Australia, with Tazbentetol proving to be a safe and effective drug with cognitive… Read More

#News